As many as 59,311 shares changed hands in the counter on BSE.

The stock witnessed a sharp setback in the recent market fall. From a high of Rs 1,682.50 on 8 May, it had tanked 30.7% in a short while to a low of Rs 1,164.45 on 14 June. From this low it recovered to Rs 1,260 by 20 June.

The stock currently trades cum-bonus for a liberal 1:1 bonus.

Dr Reddy's said it had launched Proscar drug on 20 June after Teva Pharmaceutical won a six-month US marketing exclusivity for finasteride 5 mg tablets, the chemical name of Proscar.

Meanwhile, Dr Reddy’s Lab may also shortly launch the generics version of Zocor in the US. The patent on Zocor expires on 23 June. In February, Dr Reddy’s had struck a deal with US-based Merck to sell generic versions of Zocor, if some other company won a 180-day exclusivity deal after the patent expires.

In early March 2006, Dr Reddy’s Lab had completed the acquisition of of Betapharm Group, the fourth largest generic pharmaceuticals company based in Germany, for a total enterprise value of Euro 480 million in cash.

For Q4 March 2006, Dr Reddy’s Lab reported a net loss of Rs 14 crore as compared to a loss of Rs 8.75 crore during the previous corresponding quarter. Revenues rose 40%, to Rs 496.05 crore, from a lower base.

On 30 December 2005, Dr Reddy’s Lab acquired 100% share capital of Industrias Quimicas Falcon de Mexico, S.A.De.C.V. ('Falcon'), a Roche group company for a cash consideration of Rs 232.15 crore.